🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In this trial, adolescents with obesity assigned to weekly subcutaneous semaglutide plus lifestyle intervention had a greater reduction in BMI than those who received lifestyle intervention alone. nej.md/3sz0tgw

Just in at #OW2022: Results from a post hoc analysis of Phase 3 trials evaluating treatment outcomes between race and ethnicities. For insight into the data shared today, click here: bit.ly/3UfDsdZ

Don't forget to check out the 2022 Diabetes Technology Meeting to stay up-to-date on new digital health advancements for patients with diabetes! You can click here for more information: bit.ly/3UkvHnj #2022DTM #diabetestechnology

Delilah McCarty, Senior Medial Liaison, is enjoying her time at #OW2022 and is looking forward to hearing the latest Obesity science. For ObesityWeek congress materials, you can check out: bit.ly/3UfDsdZ

Healthcare providers can share this screener form to patients to learn more about their weight loss motivation, previous attempts, and current approaches. If you are at #OW2022, you can grab a physical copy at booth #817. Otherwise check out: bit.ly/3FnKidA #NNIHCPTools

ADA guidelines strongly recommend that physicians help patients interpret continuous glucose monitoring information. Physicians can analyze the data to inform patients about lifestyle and treatment considerations for diabetes management: bit.ly/3FED2dn #2022DTM

John Lieske, M.D. has shared our results from the PHYOX3 extension trial at #KidneyWk 2022! Here, he engaged in scientific discussions alongside leading nephrologists. To learn more: bit.ly/3sohUjx

Our worldwide ONWARDS program is continuing to investigate potential treatments for diabetes. To learn more about ongoing ONWARDS clinical trials, click here: bit.ly/3vvHzIZ #DTM2022

Can continuous glucose monitoring (CGM) help improve Time In Range? The most recent ADA guidelines indicate that a range of devices may help patients stay in range. For more on these ADA guidelines, click here: bit.ly/3FED2dn #2022DTM

#AHA2022, see you soon! Feel free to visit our Scientific Booth at Booth #2511 to discuss our latest cardiovascular research. For more information, or to submit a question to our medical information team, click here: bit.ly/3FcXaTt

A phase III trial investigated a potential diabetes treatment supported by digital technology, while simulating real-world factors such as typical clinical schedules for patients and no upper limit on baseline HbA1c levels. Click here for more: bit.ly/3Ujyr4A #2022DTM

Followers of #NephTwitter-- Results from our Phase 2 study of an investigational treatment targeting oxalate overproduction have been published. Click here to learn more: bit.ly/3QKeily

Our Neuro-Health Medical team looks forward to joining Alzheimer's Disease (AD) colleagues at #CTAD2022 in San Francisco to learn about current investigations and advancements in AD clinical research. For more on our congress presence, click here: bit.ly/3H16fQt

#ASH22 attendees – we will be sharing 9 abstracts, including an oral presentation this year! If you have any questions, be sure to visit our Medical Booth #3143. For ASH congress materials, click here: bit.ly/3iRMUH6

Novo Nordisk will be sharing 26 abstracts at #ADA2023 as poster and oral presentations. For questions, you can visit Medical Booth #1335. For congress materials, click here: bit.ly/43B2TvV

New #ADA2023 Data Release: Results from ONWARDS 1, a Phase IIIa trial studying adjustments in A1C and TIR with an investigational treatment have been published. For more: bit.ly/43B2TvV

One-year results from a pragmatic clinical trial comparing the real-world effects of an approved treatment versus standard of care in US patients with uncontrolled Type 2 Diabetes were shared at #ADA2023. To read the baseline manuscript: bit.ly/3ClmjsG

PIONEER PLUS is a phase 3b, 68-week trial evaluating an investigational treatment for Type 2 Diabetes. Data from this trial was just shared at #ADA2023. For more: bit.ly/43B2TvV

Results from our Phase 3a OASIS 1 efficacy and safety trial comparing an investigational treatment for weight management to placebo have been published and presented at #ADA2023. Click here to learn more: bit.ly/43B2TvV

ONWARDS 3 & 5 head-to-head trial results presented at #ADA2023: evaluating glycemic control for insulin-naïve Type 2 Diabetes patients using an investigational medicine, with and without assistance of a dosing guide app. For more on data shared: bit.ly/43B2TvV